Navigation Links
Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
Date:7/23/2009

ing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

About the Medical College of Wisconsin: The Medical College of Wisconsin in Milwaukee, www.mcw.edu, is a private, freestanding academic institution dedicated to leadership and excellence in advancing the prevention, diagnosis and treatment of disease and injury through education, discovery, patient care and community engagement. A major national research center and academic medical center, its faculty physicians and scientists direct or collaborate on more than 3,000 research studies, publish over 1,300 peer-reviewed scientific papers, and provide care in virtually every specialty of medicine to approximately 350,000 patients annually. For more information on our transgenic services offering, see http://www.hmgc.mcw.edu/platforms/Transgenic_Core_Facility/.

About Open Monoclonal Technology, Inc.: Open Monoclonal Technology, Inc. ("OMT") is a private biotechnology company developing a new, fully human monoclonal antibody platform based on transgenic rats. The rat is a widely used laboratory animal with a well characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies. OMT's antibody platform is the result of an improve
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
2. Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M. Finzi Memorial Student Summer Fellowships to Five Students
3. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
4. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
5. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
6. Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD)
7. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
8. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
9. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
10. Why Wait for an Anti-Aging Drug? Researchers Interviewed on CBS-TVs 60 MINUTES Discover Longevinex(R) Nutriceutical Matrix Activates 9-Fold More Longevity Genes than Plain Resveratrol
11. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10New study suggests the brain predicts what eyes in motion will see 55304 1New study suggests the brain predicts what eyes in motion will see 55304 2SRNL automakers to develop high performance wireless sensors networks 9693 1SRNL automakers to develop high performance wireless sensors networks 9693 2SRNL automakers to develop high performance wireless sensors networks 9693 3New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 1New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 2New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 3New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 4New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 5